Laboratory Procedure
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.
Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials
Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.
Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation
Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
UCB Divests Mature Neurology and Allergy Portfolio in China for $680M
UCB, China, neurology, allergy, divestment, CBC Group, Mubadala, pharmaceuticals, innovation, strategic partnerships
Vertex Pharmaceuticals Sues US Government Over Fertility Assistance Program for Gene Therapy Patients
Vertex Pharmaceuticals, gene therapy, fertility assistance program, lawsuit, US government, health insurance, fertility preservation
US FTC Intensifies Patent Crusade with Investigation into Teva’s Inhaler IP
US Federal Trade Commission, Teva Pharmaceuticals, Patent Investigation, Inhaler IP, Anticompetitive Practices, Generic Competition
Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization
biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.